Phenotype switching in melanoma: implications for progression and therapy. - Wikidata - wikimedia - TriplyDB

Phenotype switching in melanoma: implications for progression and therapy.

Phenotype switching in melanoma: implications for progression and therapy.

http://www.wikidata.org/entity/Q35081779

about

NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?Adaptive Immune Resistance: How Cancer Protects from Immune Attack Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet Editorial: Cellular and Phenotypic Plasticity in Cancer.The Response of microRNAs to Solar UVR in Skin-Resident Melanocytes Differs between Melanoma Patients and Healthy Persons.MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.Acid Ceramidase in Melanoma: EXPRESSION, LOCALIZATION, AND EFFECTS OF PHARMACOLOGICAL INHIBITION Effects of a novel Nodal-targeting monoclonal antibody in melanoma Cross-talk between Dopachrome Tautomerase and Caveolin-1 Is Melanoma Cell Phenotype-specific and Potentially Involved in Tumor Progression.Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq The prognostic potential of alternative transcript isoforms across human tumors.JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma HERV-K activation is strictly required to sustain CD133+ melanoma cells with stemness features.Modeling continuum of epithelial mesenchymal transition plasticity.The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.Metastatic melanoma moves on: translational science in the era of personalized medicine.Metastatic pathways in patients with cutaneous melanoma.Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems Theory Critical role of glioma-associated oncogene homolog 1 in maintaining invasive and mesenchymal-like properties of melanoma cells MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1.Proton beam irradiation inhibits the migration of melanoma cells.LPP3 mediates self-generation of chemotactic LPA gradients by melanoma cells.Melanoma Suppressor Functions of the Carcinoma Oncogene FOXQ1.Intratumor and Intertumor Heterogeneity in Melanoma.The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone.miRNAs, Melanoma and Microenvironment: An Intricate Network.Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation.Suppression of MAPK signaling in BRAF-activated PTEN-deficient melanoma by blocking β-catenin signaling in cancer-associated fibroblasts.Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development.Mesenchymal stromal cell engagement in cancer cell epithelial to mesenchymal transition.Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy.Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model.Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma.Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity.Human Endogenous Retrovirus K in the Crosstalk Between Cancer Cells Microenvironment and Plasticity: A New Perspective for Combination Therapy.

P2860

Q26746478-EA07DE30-1747-42DD-9EC9-EF33BE1FBA05 Q26798448-4CCC0254-E444-4253-B3FF-7CA1F54409B8 Q26799864-8FAD4127-587A-42BD-8919-C86475AA0F9C Q35913063-DC035D16-1DB8-4C84-AE4A-EF65135CE1B9 Q36009638-D22F3689-3BC9-4162-8AAC-9797F9D003BE Q36320144-5FB7BEDF-6D37-4A45-A56F-3994A9801ADA Q36518353-56D2E83E-4496-4F69-AD85-429CBE4FCFDD Q36544020-10D7C09E-74AD-4845-AF85-BA6922C44E8C Q37066559-9F0C2844-6A3E-4956-802E-D6878BF10B3C Q37094024-62880F73-DCCC-4C66-B296-8A45A59973CF Q37185523-444A0368-0155-42C1-A5A1-ABB08C46289E Q37233445-252AEA00-F244-4C67-98BE-999B0A7B589B Q37609891-BE74609E-4B01-48E5-8884-FF31AA498175 Q38804042-0D7303F0-89A9-4E60-9677-40C169725FA4 Q38842819-C0152151-3B83-4E25-B7F6-B08EB667E903 Q38891959-B146BC3E-C142-4D1E-BF21-6397DA067762 Q39024316-5F6DFFEE-1825-49C0-A282-D649EFA2F767 Q39390852-676EC76B-7A62-4DA3-85B8-4D38EB4C9367 Q41247863-90D73885-85BA-4805-B110-FAC0C621B5FD Q41536617-7E2E5024-1B8E-4E88-82E2-2C6DBF6E4FD1 Q42106679-0FF58CE6-3BD5-4F38-A0B6-E15449669D06 Q42706673-2766D027-F5FE-4755-8ED5-E1F67D3D2D63 Q46312275-FED4E1EC-7942-4481-BD7E-50746B7DA099 Q46504220-0B0A345A-FE6D-4EBE-A331-B652A8CD2DC3 Q46742817-B54EDF84-A4A1-42DC-B635-E29D73429A9E Q47143125-5DEF8914-D7F5-44D7-B235-8386AA4DA38E Q47152593-672CFBF3-5780-4728-BF49-668C3603E47C Q47703891-6FED31D3-D17D-40C7-B56C-CFD28851A142 Q47768899-195E76A6-6176-45A0-9E9E-E45B388C8D71 Q48090844-3E6E22F1-8936-4A9B-AD6A-899819BCAF2C Q48162218-32B793EB-2F2D-490A-9F61-C2D456807486 Q50062276-32A6348D-5AB9-4793-8641-166620D9C92D Q51004855-E8E2554F-3022-423A-BCE6-82FC4948E642 Q51795679-EDD864D5-10D0-4ED1-BC0F-689041226096 Q52719267-F1363D71-A23F-4726-B4BB-5C5A357BBC41 Q54965855-E3BA8675-B3B8-45B7-8056-45B0C3D86EB5 Q54966511-2FEDA917-ACB9-4FD8-8838-FA612FB7AB6D Q55711521-532FC313-55FB-48DC-8FAC-CAE9FAFC06E0

P2860

Phenotype switching in melanoma: implications for progression and therapy.

http://www.wikidata.org/entity/Q35081779

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Phenotype switching in melanoma: implications for progression and therapy.

@ast

Phenotype switching in melanoma: implications for progression and therapy.

@en

type

label

Phenotype switching in melanoma: implications for progression and therapy.

@ast

Phenotype switching in melanoma: implications for progression and therapy.

@en

prefLabel

Phenotype switching in melanoma: implications for progression and therapy.

@ast

Phenotype switching in melanoma: implications for progression and therapy.

@en

P1433

Q35081779-840138E5-DAB7-47F1-8FD8-6680077A7314

P1476

Q35081779-113B8FDE-5A87-4865-8E2F-23970D2A923C

P2093

Q35081779-4B4CDA46-9533-4DF3-BD30-542120D5C2C4

Q35081779-BF306B10-501D-4A78-8742-8F85A3214A1A

Q35081779-C4B47FB0-0DE4-4C08-91F5-53ABE119E40D

P2860

Q35081779-01FF8F8F-7B62-4240-9261-28B4E953CD63

Q35081779-047D0365-3495-458E-A68E-C147AAF4B524

Q35081779-0671D661-3978-4733-AF74-EFB75B2535C3

Q35081779-08E78C34-716D-41A5-A9BC-145ABD8C6C78

Q35081779-097E9BA0-2932-4A56-9A16-B1F2BDD604A7

Q35081779-0E2E7E52-BE6A-4CE4-8132-491803727A39

Q35081779-0EAAC305-1770-4AFC-BDB0-07DB68A49628

Q35081779-0F3884DD-CD4B-4103-A511-DEA825870DAA

Q35081779-1299B806-9B0F-4DB4-927F-EE050EF9D98C

Q35081779-132957D0-B2C8-400B-B601-9432EFCFEBBA

P304

Q35081779-EC83068D-75A5-46F0-87D1-07928DE72A2D

P31

Q35081779-7956175C-A4B9-45F0-B644-A2A0EEE4CB42

P356

Q35081779-DA9AEEB5-F406-47C7-9F16-597511EB082A

P478

Q35081779-B702E30C-A7E4-4234-BCC9-28C64E05A757

P50

Q35081779-8B3E8F50-B1D1-403E-925F-BAC1448B1F4B

Q35081779-F5DE59A4-0C48-41C3-AE51-EE73D50E23EB

P577

Q35081779-5FBAEE27-4C4F-41E4-8F97-7C62F01E89E7

P5875

Q35081779-E63DC4D1-65CF-4B83-9527-1836D23F4F53

P698

Q35081779-220EEB57-C03D-4113-A694-B10A2B8331F0

P932

Q35081779-4F03A153-5A4A-4C24-9BA2-914C3087C9FB

P356

FONC.2015.00031

P1433

Frontiers in Oncology

P1476

Phenotype switching in melanoma: implications for progression and therapy.

@en

P2093

Amardeep Singh Dhillon

http://www.w3.org/2001/XMLSchema#string

Frederic Zhentao Li

http://www.w3.org/2001/XMLSchema#string

Petranel T Ferrao

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Mitf regulation of Dia1 controls melanoma proliferation and invasiveness

Dual roles of myocardin-related transcription factors in epithelial mesenchymal transition via slug induction and actin remodeling

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Epithelial-mesenchymal transitions in tumour progression

Epithelial-mesenchymal transitions in development and disease

Mutations of the BRAF gene in human cancer

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

P304

31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2015.00031

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Robin L Anderson

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273466581

http://www.w3.org/2001/XMLSchema#string

P698

25763355

http://www.w3.org/2001/XMLSchema#string

P932

4327420

http://www.w3.org/2001/XMLSchema#string